Log In Sign up
The largest database of trusted experimental protocols

Rat igg2b ltf 2

Manufactured by BioXCell
Visit Supplier
Sourced in United States

Rat IgG2b (LTF-2) is a monoclonal antibody that recognizes the IgG2b isotype in rats. It can be used for the detection and quantification of rat IgG2b in various immunological assays.

Automatically generated - may contain errors

Lab products found in correlation

Irdye 700dx nhs ester, by LI COR (1 mentions) Panitumumab, by Amgen (1 mentions) Rat igg2a 2a3, by BioXCell (1 mentions) Mannan, by Merck Group (1 mentions) Macs cd4 microbeads, by Miltenyi Biotec (1 mentions) Anti thy1.1 19e12, by BioXCell (1 mentions) Anti thy1.2 30h12, by BioXCell (1 mentions) Ls column, by Miltenyi Biotec (1 mentions) Anti cd25 pc61, by BD (1 mentions) Anti foxp3 nrrf 30, by Thermo Fisher Scientific (1 mentions) Anti mouse pd l1 10f 9g2, by BioXCell (1 mentions) Anti mouse ly6g 1a8, by BioXCell (1 mentions) Ursolic acid u6753, by Merck Group (1 mentions) Phosphate buffered saline (pbs), by GenDEPOT (1 mentions) Tryple express, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions)

8 protocols using rat igg2b ltf 2

1

EGFR-Targeted Photodynamic Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
IRDye 700DX-NHS ester was purchased from LI-COR Biosciences (Lincoln, Nevada, USA). Panitumumab, a fully humanized IgG2 mAb directed against EGFR, was purchased from Amgen (Thousand Oaks, California, USA). Anti-mouse PD-L1 (B7-H1) antibody (10F.9G2) and rat IgG2b (LTF-2; used as the control) were obtained from Bio X Cell (Lebanon, New Hampshire, USA).
Taki S., Matsuoka K., Nishinaga Y., Takahashi K., Yasui H., Koike C., Shimizu M., Sato M, & Sato K. (2021). Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. Journal for Immunotherapy of Cancer, 9(11), e003036.
+ Open protocol
+ Expand
2

CD4+ T Cell Depletion in Hpb Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
On day 0 and day 4 of secondary Hpb infection, 250 μg of anti-CD4 (GK1.5, BioXcell) or isotype control (Rat IgG2b, LTF-2; BioXcell) were injected i.v. into the tail vein of the mice. Depletion of CD4+ T cells was verified on day 8 by flow cytometry of blood samples.
Westermann S., Schubart C., Dietschmann A., Castiglione K., Radtke D, & Voehringer D. (2023). Th2-dependent STAT6-regulated genes in intestinal epithelial cells mediate larval trapping during secondary Heligmosomoides polygyrus bakeri infection. PLOS Pathogens, 19(4), e1011296.
+ Open protocol
+ Expand
3

T Cell Depletion for Tumor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice received weekly i.p. injections (400μg in 100 μl PBS) of CD8+ T cell depleting antibody (53-6.72, BioXCell) or CD4+ T cell depleting antibody (GK1.5, BioXCell) beginning 4 days prior to tumor implantation. Control animals received either rat IgG2a (2A3, BioXCell) or rat IgG2b (LTF-2, BioXCell) isotype controls for CD8+ and CD4+ T cell depletion studies respectively. Depletion was confirmed using flow cytometry.
Bucsek M.J., Qiao G., MacDonald C.R., Giridharan T., Evans L., Niedzwecki B., Liu H., Kokolus K.M., Eng J.W., Messmer M.N., Attwood K., Abrams S.I., Hylander B.L, & Repasky E.A. (2017). β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer research, 77(20), 5639-5651.
+ Open protocol
+ Expand
4

Mannan-Induced Murine Arthritis Model

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Arthritis was induced by either a single injection of 20 mg mannan (Sigma-Aldrich) intraperitoneally (Hashimoto et al., 2010 (link)), or adoptive transfer of CD4+ T cells intravenously (i.v.) (Hirota et al., 2007a (link)). CD4+ T cells were sorted from the spleen and peripheral LNs of SKG mice using MACS CD4 microbeads and LS column (Miltenyi Biotec) according to the manufacturer’s instruction. For depletion of ILCs, purified anti-Thy1.1 (19E12; Bio X cell), anti-Thy1.2 (30H12; Bio X Cell) or isotype control Rat IgG2b (LTF-2; Bio X Cell) antibody was i.v. injected. Joint swelling was scored as follows: 0, no joint swelling; 0.1, swelling of one finger joint; 0.5, mild swelling of wrist or ankle; 1.0, severe swelling of wrist or ankle. Scores for all fingers of forepaws and hindpaws, wrists and ankles were totaled for each mouse.
Hirota K., Hashimoto M., Ito Y., Matsuura M., Ito H., Tanaka M., Watanabe H., Kondoh G., Tanaka A., Yasuda K., Kopf M., Potocnik A.J., Stockinger B., Sakaguchi N, & Sakaguchi S. (2018). Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity, 48(6), 1220-1232.e5.
+ Open protocol
+ Expand
5

Antibody Panel for Mouse Immune Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rat anti-mouse CD40 mAb (FGK4.5), rat IgG2a (2A3) and rat IgG2b (LTF-2) isotype controls were purchased from BioXcell (West Lebanon, NH). Rat anti-CD4 mAb (GK1.5) was purchased from Taconic (Hudson, NY). The following antibodies were purchased from BD Biosciences (San Jose, CA): anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD45 (30-F11), anti-CD11b (M1/70), anti-Gr-1 (RB6-8C5) and anti-CD25 (PC61). The following antibodies were purchased from eBioscience (San Diego, CA): anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53–6.7), anti-IFN-γ (XMG1.2) and anti-Foxp3 (NRRF-30).
Kosaka A., Ohkuri T, & Okada H. (2014). Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer immunology, immunotherapy : CII, 63(8), 847-857.
+ Open protocol
+ Expand
6

Cell Depletion and IFNγ Neutralization in Tumor Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
100–300 μg/dose of anti-CD4 (GK1.5), anti-CD8 (2.43), anti-NK1.1 (PK136), anti-Gr1 (RB6-8C5) mAbs or Rat IgG2b (LTF-2) from BioXCell, were injected one day before therapy, concurrently with the first intratumoral injection and at days 3, 7, and 10 after the beginning of therapy. Cell depletion was validated in blood samples by flow cytometry analysis, showing a specific reduction of more than 95% of each respective cell subset. Gr1 depletion was confirmed in the tumor microenvironment on day 7 (the day of the first BO-112 injection). For IFNγ neutralization, mice were treated with 250 μg of anti-IFNγ (XMG1.2) or rat IgG the day prior to each BO-112 treatment. Then, mice were injected weekly with for depletion maintenance (100 μg/dose).
Aznar M.A., Planelles L., Perez-Olivares M., Molina C., Garasa S., Etxeberría I., Perez G., Rodriguez I., Bolaños E., Lopez-Casas P., Rodriguez-Ruiz M.E., Perez-Gracia J.L., Marquez-Rodas I., Teijeira A., Quintero M, & Melero I. (2019). Immunotherapeutic effects of intratumoral nanoplexed poly I:C. Journal for Immunotherapy of Cancer, 7, 116.
+ Open protocol
+ Expand
7

Murine Tumor Cell Injection and Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
B16F10 and TC-1 mouse tumor cell lines were purchased from ATCC and passaged in DMEM medium containing 10% FBS, 1% penicillin–streptomycin (all from Gibco) in TC-treated Cell Culture Dishes (SPL). At 70%–80% confluency, cancer cells were washed once with PBS (GenDepot) and detached using TrypLE Express (Gibco). B16F10 cells in PBS were either intravenously (1.0–4.0×105 cells), intrasplenically (5.0×105 cells), or subcutaneously (3.0×105 cells) injected into mice. TC-1 cells were intravenously injected into mice (5.0×105 cells). In indicated experiments, mice were intraperitoneally treated with either rat IgG2b (LTF-2; BioXCell) or anti-CD4 depleting antibody (GK1.5; BioXCell) at 100–200 µg/head doses every 4 to 5 days. In addition, anti-mouse CD127 (A7R34; BioXCell), anti-mouse Ly6G (1A8; BioXCell), or anti-mouse PD-L1 (10F.9G2; BioXCell) was intraperitoneally treated at 100 µg/head every 4 days. For RORγt inhibition, ursolic acid (U6753; Sigma Aldrich) dissolved in DMSO was intraperitoneally treated at 150 mg/kg every other day. For Tc17 adoptive transfer experiment, Tc17 cells generated in vitro from naïve CD8+ T cells isolated from CD45.1+ Pmel mice (3.0×106 cells) were adoptively transferred into C57BL/6 mice 1 day before B16F10 tumor intravenous injection. Mice were sacrificed on days 14–19 after tumor cell injection.
Kim B.S., Kuen D.S., Koh C.H., Kim H.D., Chang S.H., Kim S., Jeon Y.K., Park Y.J., Choi G., Kim J., Kang K.W., Kim H.Y., Kang S.J., Hwang S., Shin E.C., Kang C.Y., Dong C, & Chung Y. (2021). Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer. Journal for Immunotherapy of Cancer, 9(6), e002603.
+ Open protocol
+ Expand
8

Blocking Immune Checkpoint Molecules

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blocking mAbs to CD70 (FR70) (Oshima et al., 1998) , PD-1 (RMP1-14), BTLA (6A6), LAG3 (C97W) or agonistic mAb to CD27 (RM27-3E5) (Sakanishi and Yagita, 2010) were injected i.p. at 100 mg per mouse in 100 mL HBSS on each day of vaccination and in case of FR70 mAb also at day 9. Depleting CD8 (2.43) mAb was injected i.p. at 200 mg per mouse in 100 mL HBSS 2 days before and on each day of vaccination. In the LCMV-infection experiment, mice were injected i.v. with depleting CD4 mAb (GK1.5) at 200 mg per mouse 2 days before and 2 and 4 days after the infection. Control mice were injected with equal amounts of rat IgG2b (LTF-2) or IgG2a (2A3) isotype controls (Bio X Cell). Small-molecule inhibitor 18a (Karlstro ¨m et al., 2013) was injected i.p. at 50 mg per mouse and AMD3100 (Hatse et al., 2002) at 100 mg per mouse at days 1, 4 and 7 after the last vaccination. In adoptive transfer experiments, 18a (50 mg), AMD3100 (100 mg) and GM6001 (200 mg) were injected i.p. on the day of transfer and 24 h later. The number of repeat experiments is indicated at the end of corresponding Figure Legend.
Ahrends T., Spanjaard A., Pilzecker B., Bąbała N., Bovens A., Xiao Y., Jacobs H, & Borst J. (2017). CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity, 47(5).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!